System for providing customized myopia treatment using digital biomarkers and operating method thereof

Abstract

The present disclosure relates to digital therapeutics (DTx) for the purpose of myopia treatment including inhibiting myopia progression. The system may comprise: a measurement module for detecting eye movement of a user who is a myopia treatment subject; a collection module for collecting eye movement data related to the eye movement of the user recognized by the measurement module; a processing module for calculating a first biomarker on the basis of the collected eye movement data; and a digital task generation module for generating a first digital task on the basis of the first biomarker and providing the first digital task to the user in order to inhibit myopia progression and treating myopia in the user.

Description

A system for providing personalized myopia treatment using digital biomarkers and a method for operating the system

[0001] The present disclosure relates to digital therapeutics (hereinafter referred to as DTx) for the purpose of treating myopia, including inhibiting myopia progression, and more particularly, to a system and a method of operating the system for providing a personalized digital therapeutic using a digital biomarker.

[0002] Myopia is a highly prevalent ophthalmic condition influenced by both genetic and environmental factors. Medications (atropine), special lenses, and surgical procedures are used to treat and manage myopia, but the risk of side effects limits their clinical application. For this reason, digital therapeutics that can non-invasively and long-term control myopia progression are actively being developed.

[0003] However, current myopia treatment methods utilizing digital technology focus solely on providing general vision training programs, failing to adequately reflect the individual patient's specific needs. Specifically, the same types of tasks are provided to patients despite their varying eye size and eye movement abilities, limiting the application of personalized treatment.

[0004] Furthermore, regarding the correlation between myopia and eye movement, little is known about objective biomarkers that could serve as indicators for providing appropriate treatment to users, limiting the creation of personalized treatment modules tailored to the user's condition. Therefore, there is a need for biomarkers for providing personalized treatment modules, and for customized treatment modules utilizing these biomarkers. The present disclosure aims to address this issue.

[0005] The present disclosure provides a system and a method of operating the system for providing personalized myopia treatment using digital biomarkers.

[0006] Another object of the present disclosure is to provide an effective task for treating myopia by adjusting the ratio of eye movement tasks in a specific direction according to the user's eye movement ability or eye ratio.

[0007] Another purpose of the present disclosure is to provide customized myopia treatment to a user by calculating a digital biomarker from the user's performance results of a digital task.

[0008] Another object of the present disclosure is to derive digital biomarkers that influence myopia treatment from a user's eye movements.

[0009] Another object of the present disclosure is to provide an interface or application that enables a user to effectively perform tasks for myopia treatment using the system.

[0010] The purposes of the present disclosure are not limited to those mentioned above, and other purposes and advantages of the present disclosure not mentioned above can be understood through the following description and will be more clearly understood through the embodiments of the present disclosure. Furthermore, it will be readily apparent that the purposes and advantages of the present disclosure can be realized by the means and combinations thereof set forth in the claims.

[0011] To achieve these technical challenges, one embodiment of the present disclosure provides a system and a method of operating the system for providing personalized myopia treatment using a digital biomarker.

[0012] According to one embodiment of the present disclosure, a system for providing customized myopia treatment using a digital biomarker may include a measurement module for detecting eye movement of a user who is a subject of myopia treatment, a collection module for collecting eye movement data regarding eye movement of the user detected by the measurement module, a processing module for calculating a first biomarker based on the collected eye movement data, and a digital task generation module for generating a first digital task based on the first biomarker and providing the first digital task to the user to suppress and treat myopia progression of the user.

[0013] In one embodiment, the measurement module includes a gaze tracking type sensor, and the sensor can measure the movement distance and movement direction of the eye from the eye movement of the user.

[0014] In one embodiment, the sensor may count the number of eye movements of the user when the eye movement distance of the user exceeds a preset first threshold.

[0015] In one embodiment, the eye movement data may include the user's maximum vertical eye movement distance and the user's maximum horizontal eye movement distance.

[0016] In one embodiment, the processing module may include a preprocessing unit that processes the eye movement data or first data derived from the eye movement data and extracts key variables that can be used as digital biomarkers from the processed first data, and an analysis unit that analyzes the key variables to derive the first biomarker that affects myopia progression.

[0017] In one embodiment, the first biomarker may include an eye movement shape value, which is a ratio of the user's maximum vertical eye movement distance divided by the user's maximum horizontal eye movement distance.

[0018] In one embodiment, the first digital task may include a first sub-digital task including a first vertical eye movement task and a first horizontal eye movement task, and a second sub-digital task including a second vertical eye movement task and a second horizontal eye movement task, wherein the first sub-digital task includes more of the first vertical eye movement task than the first horizontal eye movement task, and a ratio of the first vertical eye movement task to the first horizontal eye movement task is greater than a ratio of the second vertical eye movement task to the second horizontal eye movement task, and the ratio may include a ratio of at least one of task time and number of times.

[0019] In one embodiment, the digital task generation module can generate the first sub-digital task when the eye movement shape value is less than or equal to a reference value, and can generate the second sub-digital task when the eye movement shape value exceeds the reference value.

[0020] In one embodiment, the system further comprises a display, wherein the display is capable of displaying a screen corresponding to eye movements of the user.

[0021] In one embodiment, the measurement module detects the eye movement of the user, and when the eye movement is greater than a predetermined second threshold, the display can display a screen in which a character performs a predetermined action.

[0022] In one embodiment, the digital task generation module may generate a digital task by additionally reflecting a treatment hypothesis that can control neurohumoral factors related to the mechanism of myopia.

[0023] In one embodiment, the system may further include a healthcare provider portal configured to provide a healthcare provider with one or more action options for prescribing treatment for the myopia treatment based on information received from the collection module.

[0024] In one embodiment, the collection module collects the user's performance results for the first digital task through the measurement module, the processing module calculates a second biomarker from the performance results for the first digital task, and the digital task generation module generates a second digital task for the next session based on the second biomarker and provides the second digital task to the user to suppress and treat the progression of myopia of the user.

[0025] In one embodiment, the user's performance results for the first digital task may include the user's maximum vertical eye movement distance, the user's maximum horizontal eye movement distance, and the number of eye movements of the user.

[0026] In one embodiment, the maximum vertical movement distance and the maximum horizontal movement distance may be an average of multiple performance results for each of the vertical eye movement task and the horizontal eye movement task included in the first digital task.

[0027] According to one embodiment of the present disclosure, a method of operating a system for providing customized myopia treatment using a digital biomarker may include an operation of detecting and measuring eye movements of a user who is a subject of myopia treatment by a measurement module, an operation of collecting eye movement data regarding the measured eye movements of the user by a collection module, an operation of calculating a first biomarker based on the collected eye movement data by a processing module, and an operation of generating a first digital task based on the first biomarker and providing the first digital task to the user for the purpose of suppressing and treating the progression of myopia of the user by a digital task generation module.

[0028] In one embodiment, the first biomarker may include an eye movement shape value, which is a ratio of the user's maximum vertical eye movement distance divided by the user's maximum horizontal eye movement distance.

[0029] In one embodiment, the first digital task includes a first sub-digital task including a first vertical eye movement task and a first horizontal eye movement task, and a second sub-digital task including a second vertical eye movement task and a second horizontal eye movement task, wherein a ratio of the first vertical eye movement task to the first horizontal eye movement task is greater than a ratio of the second vertical eye movement task to the second horizontal eye movement task, and the ratio may include a ratio of at least one of task time and number of times.

[0030] In one embodiment, the digital task generation module may perform an operation of generating the first sub-digital task when the eye movement shape value is less than or equal to a reference value, and may perform an operation of generating the second sub-digital task when the eye movement shape value exceeds the reference value.

[0031]

[0032] One embodiment of the present disclosure includes a program stored on a recording medium to cause a computer to execute a method according to one embodiment of the present disclosure.

[0033] One embodiment of the present disclosure includes a computer-readable recording medium having recorded thereon a program for executing a method according to one embodiment of the present disclosure on a computer.

[0034] A system and its operating method according to one embodiment of the present disclosure have the effect of providing a user with customized myopia treatment using a digital biomarker associated with myopia progression.

[0035] Additionally, according to one embodiment of the present disclosure, it is possible to provide an effective task for treating myopia by adjusting the ratio of eye movement tasks in a specific direction according to the user's eye movement ability or eye ratio.

[0036] Additionally, according to one embodiment of the present disclosure, there is an effect of being able to derive a digital biomarker that affects myopia treatment from the user's eye movements.

[0037] In addition, according to one embodiment of the present disclosure, there is an effect of being able to provide customized myopia treatment to the user by calculating a digital biomarker from the result of the user's digital task performance.

[0038] Additionally, according to one embodiment of the present disclosure, there is an effect of providing an interface or application that enables a user to effectively perform a task for myopia treatment using the system.

[0039] In addition to the above, the specific effects of the present disclosure are described together with the specific matters for carrying out the disclosure below.

[0040] FIG. 1 is a flowchart illustrating a system for providing personalized myopia treatment using a digital biomarker according to one embodiment of the present disclosure.

[0041] FIG. 2 is an expanded example diagram of a system for providing personalized myopia treatment using digital biomarkers according to one embodiment of the present disclosure.

[0042] FIG. 3 is a block diagram of a system for providing personalized myopia treatment using a digital biomarker according to one embodiment of the present disclosure.

[0043] FIG. 4 is a flowchart illustrating an operation method of a system for providing customized myopia treatment using a digital biomarker according to one embodiment of the present disclosure.

[0044] FIG. 5 is a graph measuring eye movements according to one embodiment of the present disclosure.

[0045] FIG. 6A and FIG. 6B are exemplary diagrams illustrating a method for deriving a digital biomarker from a user's eye movement data according to one embodiment of the present disclosure.

[0046] FIG. 7 is a model showing the correlation between eye movement results and myopia progression according to one embodiment of the present disclosure.

[0047] FIGS. 8A to 8C are graphs showing the correlation between eye movement results and myopia progression according to one embodiment of the present disclosure.

[0048] FIGS. 9A and 9B illustrate an interface for measuring eye movement according to one embodiment of the present disclosure.

[0049] FIGS. 10A to 10C illustrate an interface for providing a digital task according to one embodiment of the present disclosure.

[0050] To clarify the technical idea of ​​the present disclosure, embodiments of the present disclosure will be described in detail with reference to the attached drawings. In describing the present disclosure, if a detailed description of a related known function or component is determined to unnecessarily obscure the gist of the present disclosure, the detailed description will be omitted. Components having substantially the same functional configuration among the drawings are given the same reference numbers and symbols as possible even if they are shown in different drawings. For convenience of explanation, devices and methods are described together when necessary. Each operation of the present disclosure does not necessarily have to be performed in the described order and may be performed in parallel, selectively, or individually.

[0051] The terms used in the embodiments of this disclosure have been selected from widely used, current terms, taking into account the functions of the present disclosure. However, these terms may vary depending on the intentions of those skilled in the art, precedents, the emergence of new technologies, etc. Furthermore, in certain cases, the applicant may arbitrarily select terms, and in such cases, their meanings will be described in detail in the description of the relevant embodiments. Therefore, the terms used in this specification should not be defined simply as names of terms, but rather based on their meanings and the overall content of the present disclosure.

[0052] Throughout this disclosure, singular expressions may include plural expressions unless the context clearly dictates otherwise. Terms such as "comprise" or "have" should be understood to indicate the presence of a feature, number, step, operation, component, part, or combination thereof, but do not preclude the presence or addition of one or more other features, numbers, steps, operations, components, parts, or combinations thereof. In other words, when it is said throughout this disclosure that a part "comprises" a certain component, unless specifically stated otherwise, this does not mean that other components may be included, but rather that other components may be excluded.

[0053] Expressions such as "at least one" modify the entire list of elements, not individual elements of the list. For example, "at least one of A, B, and C" and "at least one of A, B, or C" refer to only A, only B, only C, both A and B, both B and C, both A and C, all of A, B, and C, or any combination thereof.

[0054] In addition, terms such as “...part”, “...module”, etc. described in the present disclosure mean a unit that processes at least one function or operation, which may be implemented as hardware or software, or a combination of hardware and software.

[0055] Throughout this disclosure, when a part is said to be "connected" to another part, this includes not only cases where the parts are "directly connected," but also cases where the parts are "electrically connected" with other elements intervening. Furthermore, when a part is said to "include" a component, this does not exclude other components, but rather includes other components, unless otherwise specifically stated.

[0056] The expression "configured to" as used throughout this disclosure can be used interchangeably with, for example, "suitable for," "having the capacity to," "designed to," "adapted to," "made to," or "capable of." The term "configured to" does not necessarily mean something is "specifically designed to" in hardware. Instead, in some contexts, the expression "a system configured to" can mean that the system is "capable of" in conjunction with other devices or components. For example, the phrase "a processor configured to perform A, B, and C" can mean a dedicated processor for performing the operations (e.g., an embedded processor), or a general-purpose processor (e.g., a CPU or application processor) that can perform the operations by executing one or more software programs stored in memory.

[0057] Throughout this disclosure, terms including ordinal numbers, such as "first," "second," etc., may be used to describe various components; however, the components are not limited by the terms. The terms are used solely to distinguish one component from another. For example, without departing from the scope of the present disclosure, a first component could be referred to as a "second component," and similarly, a second component could also be referred to as a "first component." The term "and / or" includes any combination of multiple related items or any one of multiple related items.

[0058] Throughout this disclosure, a terminal or terminal may include a UE (User Equipment), an MS (Mobile Station), a cellular phone, a smartphone, a computer, a smartwatch, a Bluetooth earphone, or a multimedia system capable of performing a communication function. Of course, the foregoing examples are not limiting.

[0059] The present disclosure relates to a system and method for providing personalized myopia treatment using digital biomarkers. More specifically, the present disclosure relates to a system and method for providing effective myopia treatment by presenting effective eye movement tasks based on the user's (patient's) ocular movement ability or eye ratio.

[0060] FIG. 1 is a flowchart illustrating a system for providing personalized myopia treatment using a digital biomarker according to one embodiment of the present disclosure.

[0061] Referring to FIG. 1, a system (10) for providing personalized myopia treatment using a digital biomarker according to one embodiment of the present disclosure may include a user terminal (100) and a server (200). In one embodiment, the user terminal (100) may be a general-purpose terminal of the user (20) or a dedicated terminal for the present disclosure. For example, the user terminal (100) may be at least one of a smartphone, a PDA, a tablet, a laptop, a PC, and a mobile communication terminal. As another example, the user terminal (100) may be a dedicated terminal provided by a hospital for the treatment of a patient. In one embodiment, the user terminal (100) may be singular or may be composed of plural user terminals.

[0062] In one embodiment, the user terminal (100) may provide myopia treatment to the user (20) by running an app (application software) for providing customized myopia treatment using a digital biomarker according to one embodiment of the present disclosure. In one embodiment, the user terminal (100) may download and install the app for providing myopia treatment according to one embodiment of the present disclosure from the server (200). In another embodiment, the user terminal (100) may download the app for providing myopia treatment according to one embodiment of the present disclosure from a separate server (not shown). For example, the user terminal (100) may download and install the app for providing myopia treatment according to one embodiment of the present disclosure through an app store provided by Google, Apple, MS, etc. In another embodiment, the user terminal (100) may access a predetermined web page to provide myopia treatment according to one embodiment of the present disclosure. For example, a user terminal (100) may access a server (200) that provides a web page for providing myopia treatment according to one embodiment of the present disclosure, thereby providing myopia treatment to a user (20). In one embodiment, the server (200) may be implemented singly or in multiples.

[0063] In one embodiment, the user terminal (100) and the server (200) are each implemented as separate devices and can be connected therebetween via a communication network (30). In one embodiment, the communication network (30) can be configured to include a wired network or a wireless network. In another embodiment, the user terminal (100) and the server (200) can be implemented in a single device. For example, the system (10) can be implemented in a single device, and the user terminal (100) and the server (200) can be internally connected.

[0064] In one embodiment, the user terminal (100) may provide the user (20) with information for myopia treatment on the display (150) or provide a digital task for the user (20) to perform for myopia treatment.

[0065] In one embodiment, the user terminal (100) can recognize and receive user's (20) behavior and / or biometric information from the measurement module (110). For example, the measurement module (110) may include a camera sensor, an eye tracking sensor, etc. provided in the user terminal (100), and as the eye tracking sensor, an infrared-based sensor, a camera-based sensor, an electrophysiological sensor, a laser-based sensor, a wearable sensor, etc. may be used.

[0066] In one embodiment, the digital task that the user terminal (100) provides to the user (20) for myopia treatment may be received from the server (200). In one embodiment, the server (200) may provide the first digital task to the user (20) based on the eye movement information of the user (20).

[0067] In one embodiment, the user terminal (100) may provide a first digital task for myopia treatment to the user (20), collect behavioral information and / or biometric information of the user (20) accordingly, and provide a second digital task based on the collected performance results of the user (20) for the first digital task.

[0068] FIG. 2 is an expanded example diagram of a system for providing personalized myopia treatment using digital biomarkers according to one embodiment of the present disclosure.

[0069] Referring to FIG. 2, a system (10, see FIG. 1) for providing personalized myopia treatment using a biomarker according to one embodiment of the present disclosure may further include a healthcare provider portal (300) configured to provide a healthcare provider (40) with one or more action options for prescribing a treatment for myopia treatment. For example, a healthcare provider (40) may use the healthcare provider portal (300) to create a prescription plan for a user (20) and check the user's (20) adherence to the task and progress of the task.

[0070] In one embodiment, the system (10) may derive a first biomarker from eye movement data regarding eye movements of a user (20) detected by a measurement module (110, see FIG. 1), and generate a first digital task to be provided to the user (20) based on the first biomarker. For example, the process of derive the first biomarker from the eye movement results of the user (20) may include a process of preprocessing eye movement data (such as data quality check, data cleaning, or data alignment) and a process of analyzing the data (such as descriptive analysis, correlation and mixed-effects model application) to derive (or evaluate the effect of) a biomarker that affects myopia progression.

[0071] In one embodiment, the system (10) may determine a digital task to provide to the user (20) for myopia treatment based on a prescription provided by a healthcare provider (40) through the healthcare provider portal (300).

[0072] In one embodiment, the user terminal (100) can determine a digital task to be provided to the user (20) for myopia treatment based on the eye movement information of the user (20) using an app for providing myopia treatment according to one embodiment of the present disclosure.

[0073] In one embodiment, the system (10) may include a gaze-tracking sensor (not shown). For example, the gaze-tracking sensor may be used to detect eye movements of a user and represent the eye movements as coordinate (x, y) data. Here, the gaze-tracking sensor may include, but is not limited to, an infrared-based sensor, a camera-based sensor, an electrophysiological sensor, a laser-based sensor, a wearable sensor, etc.

[0074] FIG. 3 is a block diagram of a system for providing personalized myopia treatment using a digital biomarker according to one embodiment of the present disclosure.

[0075] Referring to FIG. 3, a system (10) for providing customized myopia treatment using a biomarker according to one embodiment of the present disclosure may include a measurement module (110) for detecting eye movement of a user (20, see FIG. 1) who is a subject of myopia treatment, a collection module (120) for collecting eye movement data regarding eye movement of the user (20) detected by the measurement module (110), a processing module (130) for calculating a first biomarker based on the eye movement data of the user (20), a digital task generation module (140) for generating a first digital task based on the first biomarker and providing the first digital task to the user (20) for suppressing and treating myopia progression of the user (20), and a display (150) for displaying a screen corresponding to the eye movement of the user (20).

[0076] In one embodiment, the measurement module (110) may include a sensor capable of detecting the movement of the user's eyes. For example, the measurement module (110) may include a gaze-tracking type sensor (not shown), and the sensor may measure the movement distance and movement direction of the eye from the eye movement of the user (20). In one embodiment, the measurement module (110) may further measure the number of eye movements of the user (20) using the sensor.

[0077] In one embodiment, the measurement module (110) may be implemented in a form included in the user terminal (100). For example, it may be implemented as a camera or gaze tracking sensor equipped in the user terminal (100). In another embodiment, the measurement module (110) may be implemented as a separate device from the user terminal. For example, the measurement module (110) may be implemented as a separate device including at least one of a camera, an infrared sensor, a wearable gaze tracking sensor, a radar sensor, and an electrode sensor.

[0078] In one embodiment, the processing module (130) may include a preprocessing unit (131) that processes eye movement data or first data derived from the eye movement data and extracts key variables that can be used as digital biomarkers, and an analysis unit (132) that analyzes the key variables to derive a first biomarker that affects myopia progression. In another embodiment, the processing module (130) may derive a second biomarker from the performance results for the first digital task.

[0079] In one embodiment, the preprocessing unit (131) can process the eye movement data (raw data) of the user (20) stored in the collection module (120) into a form suitable for analysis. In another embodiment, the preprocessing unit (131) can process data regarding the performance results of the user (20) for the first digital task stored in the collection module (120) into a form suitable for analysis.

[0080] For example, the preprocessing unit (131) can extract key variables that can be used as digital biomarkers by checking for omissions, outliers, or duplications in the collected eye movement data (quality check), resolving data problems discovered during the quality check process (data purification), and sorting the data according to specific criteria (time, user ID, time order, etc.).

[0081] In one embodiment, the key variables that can be used as digital biomarkers may include at least one of the user's (20) vertical eye movement distance, the user's horizontal eye movement distance, the eye movement shape value, which is the ratio of the maximum vertical eye movement distance divided by the user's maximum horizontal eye movement distance, and the number of eye movements.

[0082] In one embodiment, the analysis unit (132) can analyze the characteristics of key variables, the correlations between key variables, and the relationship between key variables and myopia progression to derive a first biomarker that affects myopia progression. For example, myopia progression can be determined from the user's (20) spherical equivalent refractive error (SER) value or cycloplegic refractive error (CRE) value. However, this is merely an example, and various biometric data that can determine the user's (20) myopia progression can be utilized.

[0083] In another embodiment, the analysis unit (132) may analyze the relationship between key variables extracted from the user's performance results for the first digital task and myopia progression to derive a second biomarker that affects myopia progression.

[0084] For example, the analysis unit (132) may use the Pearson Correlation method to analyze the relationship between myopia progression and major variables, and may apply the Conditional Inference Tree (CTree) method to derive a cutoff value, which is a boundary value at which the influence of major variables on myopia progression changes.

[0085] In one embodiment, the digital task generation module (140) can generate the first digital task by additionally reflecting a treatment hypothesis that can control neurohumoral factors related to the mechanism of myopia.

[0086] In one embodiment, the digital task generation module (140) may generate a second digital task for the next session based on the second biomarker and provide it to the user (20) to suppress and treat the progression of myopia of the user (20).

[0087] In one embodiment, the measurement module (110), the collection module (120), the processing module (130), and the digital task creation module (140) are described as being included in the user terminal (100), but this is only for convenience of explanation, and they may be included in the user terminal (100), or further, they may be included separately in the user terminal (100) and the server (200), and thus are not limited by the execution subject.

[0088] FIG. 4 is a flowchart illustrating an operation method of a system for providing customized myopia treatment using a digital biomarker according to one embodiment of the present disclosure.

[0089] In step S410, the measurement module (110) can measure the eye movements of the user (20). For example, the eye movements can be measured by displaying a screen presenting a preliminary task for measuring eye movements on the display (150) and having the user (20) perform the preliminary task.

[0090] In one embodiment, the measurement module (110) includes a gaze-tracking type sensor, and the sensor can measure the distance and direction of eye movement from the eye movement of the user (20). In one embodiment, the measurement module (110) can measure the number of eye movements of the user (20) using the sensor.

[0091] In step S420, the collection module (120) may collect eye movement data regarding eye movement of the user (20) recognized by the measurement module (110). In one embodiment, the eye movement data of the user (20) may include the maximum vertical eye movement distance of the user (20) and the maximum horizontal eye movement distance of the user. In one embodiment, the eye movement data of the user (20) may further include the number of eye movements of the user (20).

[0092] In step S430, the processing module (130) may calculate a first biomarker based on the eye movement data of the user (20). In one embodiment, the processing module (130) may include a preprocessing unit that processes the eye movement data or the first data calculated from the eye movement data and extracts key variables that can be used as a digital biomarker from the processed data, and an analysis unit that analyzes the key variables to derive a first biomarker that affects myopia progression. In one embodiment, the first biomarker may include an eye movement shape value, which is a ratio of the maximum vertical movement distance of the user (20) divided by the maximum horizontal movement distance of the user's eye.

[0093] In step S440, the digital task generation module (140) can check whether the eye movement shape value is lower than or equal to a predetermined reference value, and provide the user (20) with a first digital task configured with different eye movement directions at different ratios according to the eye movement shape value. For example, the predetermined reference value may be a cutoff value, which is a boundary value at which the influence of the eye movement shape value on myopia progression changes. Specifically, when the eye movement shape value is lower than or equal to the cutoff value (when the eye movement shape is close to an ellipse, where an ellipse means an ellipse whose major axis is horizontal), the change in SER affecting myopia progression relatively increases (myopia progresses), and when the eye movement shape value is higher than or equal to the cutoff value (when the eye movement shape is close to a circle), the change in SER tends to decrease. In addition, since there is a tendency for SER to decrease as the number of vertical eye movements increases when the eye movement form value is below the cutoff value, providing the user (20) with a customized first digital task composed of different eye movement directions at different ratios according to the eye movement form value of the user (20) has the effect of optimizing the effectiveness of myopia treatment.

[0094] In one embodiment, the digital task generation module (140) may provide a customized digital task based on eye movement pattern values. The first digital task may include a first sub-digital task and a second sub-digital task. The first sub-digital task may include a first vertical eye movement task and a first horizontal eye movement task. The second sub-digital task may include a second vertical eye movement task and a second horizontal eye movement task. In one embodiment, the first sub-digital task may include more first vertical eye movement tasks than the first horizontal eye movement tasks. For example, the first sub-digital task may include more first vertical eye movement tasks than the first horizontal eye movement tasks based on task time or number of times. Including the first vertical eye movement task more than the first horizontal eye movement task means that the sum of the first vertical eye movement task times is greater than the sum of the first horizontal eye movement task times, or the number (or number of times) of the first vertical eye movement tasks is greater than the number (or number of times) of the first horizontal eye movement tasks, or the sum and number (or number) of the first vertical eye movement task times are greater than the sum and number (or number) of the first horizontal eye movement tasks.

[0095] In one embodiment, the first sub-digital task may have a greater ratio of vertical eye movement tasks to horizontal eye movement tasks than the second sub-digital task. That is, the ratio of the first vertical eye movement to the first horizontal eye movement (task time (or number of times) of the first vertical eye movement task / task time (or number of times) of the first horizontal eye movement task) may be greater than the ratio of the second vertical eye movement to the second horizontal eye movement (task time (or number of times) of the second vertical eye movement task / task time (or number of times) of the second horizontal eye movement task).

[0096] In one embodiment, the digital task generation module (140) may provide a first sub-digital task to the user (20) if the eye movement shape value is below a reference value (step S450a). Conversely, if the eye movement shape value exceeds the reference value, the digital task generation module (140) may provide a second sub-digital task to the user (20) (step S450b).

[0097] In step S460, the process of the user terminal (100) providing a digital task to the user (20), measuring the eye movements of the user (20) accordingly, and presenting a digital task to the user (20) again based on the same may be repeated until a predetermined criterion (e.g., number of times provided N) is satisfied. In one embodiment, the collection module (120) collects the performance results of the user (20) for the first digital task through the measurement module (110), the processing module (130) calculates a second biomarker from the performance results of the first digital task, and the digital task generation module (140) generates a second digital task for the next round based on the second biomarker to provide the second digital task to the user (20) in order to suppress and treat myopia progression of the user (20).

[0098] FIG. 5 is a graph measuring eye movements according to one embodiment of the present disclosure. Specifically, (A) shown in FIG. 5 is a graph measuring a user's vertical eye movements, and (B) shown in FIG. 5 is a graph measuring a user's horizontal eye movements.

[0099] Referring to (A) of FIG. 5, the graph represents the distance (y-axis) that the user (20) alternately moves the eyeball in the vertical upward and downward directions over time (x-axis). The two dashed lines drawn horizontally on the graph of FIG. 5 (A) represent a first threshold predetermined for counting eyeball movements. In one embodiment, the measurement module (110) may measure the number of eyeball movements of the user (20) using a sensor, and count the number of eyeball movements of the user (20) when the eyeball movement distance of the user (20) exceeds the first threshold predetermined. The maximum vertical movement distance (amplitude) of the eyeball movement for which the movement is counted may be obtained from the point indicated by the peak value of the graph of FIG. 5 (A).

[0100] FIG. 5(B) is a graph measuring horizontal eye movements of a user (20). Referring to FIG. 5(B), the graph represents the distance (y-axis) that the user (20) moves his / her eyes alternately in the horizontal left-right direction over time (x-axis). The two dashed lines drawn horizontally on the graph of FIG. 5(B) represent a first threshold predetermined for counting eye movements. In one embodiment, the measurement module (110) may measure the number of eye movements of the user (20) using a sensor, and count the number of eye movements of the user (20) when the eye movement distance of the user (20) exceeds the first threshold predetermined. The maximum horizontal movement distance (amplitude) of the eye movement for which movement is counted may be obtained from the point indicated by the peak value of the graph of FIG. 5(B).

[0101] FIG. 6A and FIG. 6B are exemplary diagrams illustrating a method for deriving a digital biomarker from a user's eye movement data according to one embodiment of the present disclosure.

[0102] FIG. 6A is an exemplary diagram illustrating a method for calculating a digital biomarker from eye movement data of a user (20). Referring to FIG. 6A, a movement distance ratio (MDR) may be calculated by dividing the maximum vertical eye movement distance of the user (20) by the maximum horizontal eye movement distance. For example, if the maximum vertical movement distance is 21.3 and the maximum horizontal movement distance is 46.4, the MDR is calculated as 21.3 / 46.4 = 0.46. The movement distance ratio is a value indicating the vertical and horizontal eye movement patterns of the user, and thus may be replaced with the term “eye movement pattern value.” In one embodiment, the first biomarker may include an eye movement pattern value, which is a ratio of the maximum vertical eye movement distance of the user (20) divided by the maximum horizontal eye movement distance of the user.

[0103] FIG. 6B is an exemplary diagram illustrating a method for calculating a digital biomarker from a performance result of a digital task performed by a user (20). Referring to FIG. 6B, an eye movement pattern value can be calculated from a performance result of an eye movement task performed by a user (20). In one embodiment, the performance result of the user (20) for the first digital task may include the maximum vertical eye movement distance of the user (20), the maximum horizontal eye movement distance of the user (20), and the number of eye movements of the user (20). For example, the maximum vertical movement distance and the maximum horizontal movement distance may be an average value of the performance results of the vertical eye movement task and the horizontal eye movement task included in the first digital task, respectively. Specifically, horizontal eye movement tasks game1 (G1) and game5 (G5) and vertical eye movement task game3 (G3) are provided to the user (20), and vertical movement, horizontal movement, and eye movement count data can be extracted from the average value of the performance results. Eye movement form values ​​can be calculated by dividing the vertical movement value by the horizontal movement value among the extracted data.

[0104] FIG. 7 is a model showing the correlation between eye movement results and myopia progression according to one embodiment of the present disclosure.

[0105] Referring to FIG. 7, Model 1 is a model that can predict the progression of myopia of a user based on the user's eye movement shape value and horizontal movement distance, and predicts that the degree of myopia progression is low when the eye movement shape is almost circular [when the eye movement shape value (Eye movement Shape, ES) is greater than the reference value (cutoff value)], and that the degree of myopia progression is high when the eye movement shape is close to an oval [when the eye movement Shape, ES is less than the reference value (cutoff value)]. In one embodiment, Model 2 is a model for explaining the correlation between various major variables and the effect of myopia treatment when the eye movement shape is close to an oval (when myopia progression is predicted).

[0106] Model 1 is intended to predict the degree of myopia progression of a user [as a one-year change in the user's spherical equivalent refractive error (SER) or cycloplegic refractive error (CRE)] based on the user's eye movement form value (ES) and horizontal movement distance (HMD). The formula of Model 1 according to one embodiment of the present disclosure is as follows.

[0107]

[0108] [Formula 1]

[0109]

[0110]

[0111] Here, myopia progression is the one-year change in spherical equivalent refractive error (SER) or cycloplegic refractive error (CRE), ES is the ocular movement form value (ES), HMD is the average of horizontal movement distance (HMD), and ES*HMD is the interactive term of ES and HMD. are weighting coefficients.

[0112] According to Model 1, the larger the eye movement shape value (ES) is than the reference value (the closer the eye movement shape is to a circle), the more the change in CRE is minimized (i.e., myopia progression is suppressed) in relation to the horizontal movement distance (HMD), and the smaller the eye movement shape value is than the reference value (the closer the eye movement shape is to an ellipse), the more the change in CRE is increased (i.e., myopia progression is suppressed).

[0113] Model 2 is intended to predict myopia progression [as a one-year change in the user's spherical equivalent refractive error (SER) or cycloplegic refractive error (CRE)] based on the user's eye movement form value (ES), horizontal movement distance (HMD), and vertical movement count (VMC) when the eye movement form value (ES) is below a reference value (when the eye movement form is close to an ellipse). The formula of Model 2 according to one embodiment of the present disclosure is as follows.

[0114] [Formula 2]

[0115]

[0116]

[0117] Here, myopia progression is the one-year change in spherical equivalent refractive error (SER) or cycloplegic refractive error (CRE), ES is the ocular movement form value (ES), HMD is the mean of horizontal movement distance, VMC is the mean of vertical movement count, ES*HMD is the interactive term of ES and HMD, and ES*VMC is the interactive term of ES and VMC. are weighting coefficients.

[0118] According to Model 2, when the ocular movement form value (ES) is below the reference value (when the ocular movement form is close to an ellipse), the number of vertical eye movements influences myopia treatment. Specifically, the clinical trial statistically confirmed that when the ocular movement form value is small, an increase in the number of vertical eye movements (VMC) tends to decrease the change in CRE (suppressing myopia progression).

[0119] FIGS. 8A to 8C are graphs showing the correlation between eye movement results and myopia progression according to one embodiment of the present disclosure.

[0120] Figure 8a is a scatter plot showing the relationship between eye movement shape value (or MDR) and SER change.

[0121] Referring to Figure 8a, a significant correlation was observed between SER changes and MDR, and it can be confirmed that the higher the MDR ratio (the closer the eye movement shape is to a circular one), the less the SER change (the more myopia progression is suppressed). The closer the SER change value is to 0, the more the myopia progression is slowed.

[0122] Figure 8b is a regression line graph of predicted changes in the number of vertical eye movements (VMC) and SER changes at different eye movement shape values ​​(or MDR) and horizontal movement distance (HMD).

[0123] Graphs (1), (2), and (3) in Fig. 8b are regression line graphs of predicted changes in the number of vertical eye movements and SER changes for the 25%, 50%, and 75% distributions of each HMD value. Each graph shows that as the MDR decreases and the VMC increases, the SER change tends to decrease (suppress myopia progression). In particular, graph (2) shows that when the VMC is maximum and the HMD belongs to the 50% quartile, the change in SER can reach 0 (no myopia progression, effective in suppressing myopia progression) even at a small MDR.

[0124] Figure 8c is a graph showing the relationship between the number of vertical eye movements and the degree of myopia progression for cases with different eye movement shape values ​​(or eye shapes).

[0125] Referring to Figure 8c, the closer the eye movement shape is to an ellipse (the smaller the eye movement shape value), the more the effect of reducing myopia progression due to an increase in the number of eye movements in the vertical direction is maximized (a rapid decreasing pattern is shown).

[0126] FIGS. 9A and 9B each illustrate an interface for measuring eye movement according to one embodiment of the present disclosure.

[0127] Referring to FIG. 9A, the system (10) may provide the user (20) with an interface that presents a preliminary task for measuring eye movements on the display (150). For example, the system (10) may indicate the direction in which the user (20) should move his or her eyes through an arrow (152) or an eye movement guidance animation (153) on the display (150).

[0128] In one embodiment, the system (10) can use the measurement module (110) to determine whether the user (20) is looking straight at the display (150) from an appropriate distance. For example, the system (10) can display at the bottom of the interface screen whether the user (20) is maintaining an appropriate distance (154) or looking straight at the display (150) (155).

[0129] Referring to FIG. 9b, the system (10) can display changes in the character (151) according to the eye movement on the display (150) when the user (20) moves his / her eyes in the direction indicated by the system (10). In one embodiment, the system (10) detects the eye movement of the user (20) using the measurement module (110), and when the eye movement is greater than a predetermined second threshold, the display (150) can display a screen in which the character (151) performs a predetermined action. For example, the character (151) can move in the direction in which the user's eyes move.

[0130] FIGS. 10A to 10C illustrate an interface for providing a digital task according to one embodiment of the present disclosure.

[0131] FIGS. 10A and 10B illustrate an interface for providing a vertical eye movement task according to one embodiment of the present disclosure.

[0132] Referring to FIG. 10A, the system (10) may provide a digital task to the user (20) via the display (150). For example, the system (10) may display an arrow (152) on the display (150) indicating the direction in which the user (20) should move his or her eyes, and may instruct the user (20) on his or her actions via a guidance message such as "Look up." In one embodiment, the display (150) may provide the user (20) with a timer (156) indicating the progress of the digital task.

[0133] Referring to FIG. 10b, when the user (20) moves his / her eyes in a direction indicated in a digital task, the system (10) can display changes in the character (151) according to the eye movement on the display (150). In one embodiment, the system (10) detects the eye movement of the user (20) using the measurement module (110), and when the eye movement is greater than a predetermined second threshold, the display (150) can display a screen in which the character (151) performs a predetermined action. For example, when the user (20) looks upward at a certain level (70% of the maximum eye movement value) and for a certain period of time (1100 ms), the character (151) can move in the direction in which the user's eyes move. In another embodiment, the character (151) moves in real time in response to the eye movements of the user (20), and the system (10) can determine that the task has been completed when the user (20) looks upward at a certain level (70% of the maximum eye movement value) and for a certain period of time (1100 ms).

[0134] FIG. 10C illustrates an interface for providing a horizontal eye movement task according to one embodiment of the present disclosure. Referring to FIG. 10C, the system (10) may provide a digital task to a user (20) through a display (150). For example, the system (10) may provide an interface to the user (20) including a character (151) moving along the eye of the user (20) on the display (150) and an object (157) moving down from the top to the bottom over time. In one embodiment, the system (10) may detect the eye movement of the user (20) using the measurement module (110), and if the eye movement is greater than a predetermined second threshold, may display a screen on the display (150) in which the character (151) performs a predetermined action. For example, if a user (20) looks in one direction for a certain level (70% of the maximum eye movement value) and a certain period of time (800 ms), the character (151) can move in the direction in which the user's eyes move (the side rail). If there is an object (157) in a certain area of ​​the rail where the character (151) is, the character (151) can acquire the object (157). The system (10) allows the user (20) to perform a horizontal eye movement task by having the character (151) collect as many objects (157) as possible during a certain period of time (156).

[0135] An embodiment of the present disclosure may also be implemented in the form of a recording medium containing computer-executable instructions, such as program modules, executed by a computer. Computer-readable media may be any available media that can be accessed by a computer, and includes both volatile and nonvolatile media, removable and non-removable media. Furthermore, computer-readable media may include both computer storage media and communication media. Computer storage media includes both volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storing information, such as computer-readable instructions, data structures, program modules, or other data. Communication media typically contains computer-readable instructions, data structures, or program modules, and includes any information delivery media.

[0136] The above description of the present disclosure is provided for illustrative purposes only, and those skilled in the art will readily appreciate that the present disclosure can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, components described as being single may be implemented in a distributed manner, and similarly, components described as being distributed may be implemented in a combined manner.

[0137] The scope of the present disclosure is indicated by the claims described below rather than the detailed description above, and all changes or modifications derived from the meaning and scope of the claims and their equivalent concepts should be interpreted as being included in the scope of the present disclosure.

[0138] [Explanation of symbols]

[0139] 10: A system that provides personalized myopia treatment using digital biomarkers.

[0140] 100: User terminal

[0141] 110: Measurement module

[0142] 120: Collection Module

[0143] 130: Processing module

[0144] 131: Preprocessing unit

[0145] 132: Analysis Department

[0146] 140: Digital Task Creation Module

[0147] 150: Display

[0148] 151: Character

[0149] 152: Arrow

[0150] 153: Guide Animation

[0151] 154: Keep a safe distance icon

[0152] 155: Front view icon

[0153] 156: Timer

[0154] 157: Object

[0155] 200: Server

[0156] 300: Healthcare Provider Portal

[0157] 20: User

[0158] 30: Network

[0159] 40: Healthcare Providers

Claims

1. A system that provides customized myopia treatment using a digital biomarker. A measurement module that detects eye movements of a user who is a subject of myopia treatment; A collection module that collects eye movement data regarding the user's eye movement recognized by the above measurement module; A processing module that calculates a first biomarker based on the collected eye movement data; and In order to suppress and treat the progression of myopia of the user, a digital task generation module is provided to the user by generating a first digital task based on the first biomarker; A system that provides personalized myopia treatment using digital biomarkers.

2. In paragraph 1, The above measurement module includes a gaze tracking type sensor, The above sensor measures the movement distance and movement direction of the eye from the eye movement of the user. A system that provides personalized myopia treatment using digital biomarkers.

3. In paragraph 2, The above sensor counts the number of eye movements of the user when the eye movement distance of the user exceeds a preset first threshold. A system that provides personalized myopia treatment using digital biomarkers.

4. In paragraph 1, The above eye movement data is, Including the maximum vertical movement distance of the user's eye and the maximum horizontal movement distance of the user's eye, A system that provides personalized myopia treatment using digital biomarkers.

5. In paragraph 1, The above processing module, A preprocessing unit that processes the eye movement data or the first data derived from the eye movement data and extracts key variables that can be used as digital biomarkers from the processed first data; and An analysis unit that analyzes the above-mentioned major variables to derive the first biomarker that affects myopia progression; A system that provides personalized myopia treatment using digital biomarkers.

6. In paragraph 1, The above first biomarker is, Including an eye movement shape value, which is a ratio of the maximum vertical movement distance of the user's eye to the maximum horizontal movement distance of the user's eye. A system that provides personalized myopia treatment using digital biomarkers.

7. In paragraph 6, The first digital task includes a first sub-digital task including a first vertical eye movement task and a first horizontal eye movement task, and a second sub-digital task including a second vertical eye movement task and a second horizontal eye movement task, The first sub-digital task includes more of the first vertical eye movement task than the first horizontal eye movement task, The ratio of the first vertical eye movement task to the first horizontal eye movement task is greater than the ratio of the second vertical eye movement task to the second horizontal eye movement task, The above ratio includes at least one of the task time and number of times. A system that provides personalized myopia treatment using digital biomarkers.

8. In paragraph 7, The above digital task creation module If the above eye movement shape value is less than or equal to the reference value, the first sub-digital task is generated, If the above eye movement shape value exceeds the reference value, the second sub-digital task is generated. A system that provides personalized myopia treatment using digital biomarkers.

9. In paragraph 1, Including more displays, The above display displays a screen corresponding to the user's eye movements, A system that provides personalized myopia treatment using digital biomarkers.

10. In paragraph 9, The above measurement module detects the eye movement of the user, and if the eye movement is greater than a predetermined second threshold, The above display shows a screen where a character performs a predetermined action. A system that provides personalized myopia treatment using digital biomarkers.

11. In paragraph 1, The above digital task creation module is, To generate the first digital task by additionally reflecting the therapeutic hypothesis that can control the neurohumoral factors related to the developmental mechanism of myopia, A system that provides personalized myopia treatment using digital biomarkers.

12. In paragraph 1, Further comprising a healthcare provider portal configured to provide a healthcare provider with one or more action options for prescribing treatment for said myopia treatment based on information received from said collection module. A system that provides personalized myopia treatment using digital biomarkers.

13. In paragraph 1, The above collection module collects the user's performance results for the first digital task through the measurement module, The above processing module calculates a second biomarker from the performance result for the first digital task, The above digital task generation module generates a second digital task for the next round based on the second biomarker and provides it to the user in order to suppress and treat the progression of myopia of the user. A system that provides personalized myopia treatment using digital biomarkers.

14. In paragraph 13, The user's performance results for the above first digital task are as follows: Including the maximum vertical movement distance of the user's eye, the maximum horizontal movement distance of the user's eye, and the number of eye movements of the user. A system that provides personalized myopia treatment using digital biomarkers.

15. In paragraph 14, The above maximum vertical movement distance and the above maximum horizontal movement distance are, The average value of multiple performance results for each of the vertical eye movement task and horizontal eye movement task included in the first digital task above, A system that provides personalized myopia treatment using digital biomarkers.

16. A method of operating a system that provides customized myopia treatment using a digital biomarker, An action of detecting and measuring eye movements of a user who is a subject of myopia treatment by a measurement module; An action of collecting eye movement data regarding the eye movement of the user measured by the collection module; An operation of calculating a first biomarker based on the collected eye movement data by the processing module; and An operation of generating a first digital task based on the first biomarker and providing the first digital task to the user to suppress and treat the progression of myopia of the user by a digital task generation module; A method of operation of a system for providing personalized myopia treatment using digital biomarkers.

17. In paragraph 16, The above first biomarker is, Including an eye movement shape value, which is a ratio of the maximum vertical movement distance of the user's eye to the maximum horizontal movement distance of the user's eye. A method of operation of a system for providing personalized myopia treatment using digital biomarkers.

18. In paragraph 17, The first digital task includes a first sub-digital task including a first vertical eye movement task and a first horizontal eye movement task, and a second sub-digital task including a second vertical eye movement task and a second horizontal eye movement task, and the ratio of the first vertical eye movement task to the first horizontal eye movement task is greater than the ratio of the second vertical eye movement task to the second horizontal eye movement task, The above ratio includes at least one of the task time and number of times. A method of operation of a system for providing personalized myopia treatment using digital biomarkers.

19. In paragraph 18, The above digital task creation module is, If the above eye movement shape value is less than or equal to the reference value, an operation for generating the first sub-digital task is performed, If the above eye movement form value exceeds the reference value, an operation of generating the second sub-digital task is performed. A method of operation of a system for providing personalized myopia treatment using digital biomarkers.

20. A computer program stored on a computer-readable recording medium recording a program for executing the method of any one of claims 16 to 19.

Images